Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972320 | 0.84 | NPSR1 (0.68) | NPSR1ALDH1A1POLBP2RX1LMNA | |
| SCHEMBL27820148 | 0.81 | GAA (0.61) | NPSR1ALDH1A1POLBP2RX1LMNA | |
| SCHEMBL1972781 | 0.81 | ALDH1A1 (0.63) | NPSR1ALDH1A1POLBP2RX1LMNA | |
| SCHEMBL14045943 | 0.80 | NPSR1 (0.61) | NPSR1ALDH1A1POLBP2RX1LMNA | |
| SCHEMBL29286689 | 0.79 | LMNA (0.72) | NPSR1ALDH1A1P2RX1LMNAPTGS1 | |
| SCHEMBL30137430 | 0.79 | NPSR1 (0.69) | NPSR1ALDH1A1POLBP2RX1LMNA | |
| SCHEMBL29646460 | 0.79 | GAA (0.68) | NPSR1ALDH1A1POLBP2RX1LMNA | |
| SCHEMBL1127884 | 0.79 | GAA (0.68) | NPSR1ALDH1A1POLBP2RX1LMNA | |
| SCHEMBL1417591 | 0.79 | NPSR1 (0.69) | NPSR1ALDH1A1POLBP2RX1LMNA | |
| SCHEMBL27836968 | 0.78 | NPSR1 (0.52) | NPSR1ALDH1A1POLBP2RX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103391931-A | A method of treating liver fibrosis | PFIZER LTD | 2013-11-13 | — | — | CN | disclosed |
| CN-102153539-A | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORP | 2011-08-17 | — | — | CN | disclosed |
| US-7572813-B2 | Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents; N-[2-[[(cis) -2-[[1- (4-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1565436-A4 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060135502-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT | 2006-06-22 | — | — | US | disclosed |
| US-7045521-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| CN-1741994-A | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORP (US) | 2006-03-01 | — | — | CN | disclosed |
| WO-2005079496-A2 | SUBSTITUTED BICYCLOALKYLAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040110736-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT (US) | 2004-06-10 | — | — | US | disclosed |
| US-6706712-B2 | RHEUMATIC DISEASES, MULTIPLE SCLEROSIS, ASTHMA, ANTICHOLESTEROL AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
| EP-1343751-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-02 | — | — | US | disclosed |
| WO-2002060859-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110736-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | NPSR1 298/4885ALDH1A1 1095/4885POLB 1862/4885 |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | NPSR1 298/4885ALDH1A1 1095/4885POLB 1862/4885 |
| US-20060135502-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | NPSR1 302/4885ALDH1A1 1345/4885POLB 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.